Increased expression of BTG1 and BTG2 was mainly associated with increased survival advantage, where BTG1 predicted better prognosis of patients with BRCA, HNSC, LUSC, SARC, UVM, and BTG2 predicted better prognosis for BLCA, LUAD, MESO, SARC, SKCM. This evidence concerns the gene BTG1 and bladder transitional cell carcinoma.